OSLO/LONDON, May 28th 2021: EXACT THERAPEUTICS AS ("EXACT-Tx", Euronext Growth:
EXTX), a clinical stage precision medicine company utilizing Acoustic Cluster
Therapy (ACT®) across multiple therapeutic areas, today provided an update
regarding the ongoing phase I ACTIVATE study.
Enrolment of patients in the study at the Royal Marsden Hospital in London has
been adversely impacted through the Covid-19 pandemic period. There have been
seven patients enrolled in the study with five patients' data evaluable to date.
A number of valuable and encouraging insights have been gained from this first
cohort of treated patients, particularly with respect to application of
In addition, as the organisation has expanded with appointment of experienced
senior executives, focus has increased on improving quality management and
internal governance processes. As a consequence, robust internal governance
processes have been developed and implemented.
In parallel, a protocol amendment is planned with a consequent impact on patient
enrolment, which is anticipated to restart in Q4 2021.
This additional foundational work will provide a strong platform to evaluate the
exciting potential of Acoustic Cluster Therapy in oncology and other therapeutic
For more information contact:
Dr Rafiq Hasan, CEO
Optimum Strategic Communications
Mary Clark/ Hollie Vile/ Manel Mateus
Tel: +44 (0) 203 922 1906
EXACT-Tx is a clinical stage Norwegian biotech company developing a technology
platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®).
ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug
enhancement - with the potential to significantly amplify the clinical utility
of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy), infectious diseases,
and neurological conditions. www.exact-tx.com
o ACT® comprises a proprietary formulation consisting of microbubbles and
microdroplets that is activated through the application of ultrasound with the
consequent increase in targeted delivery of a co-administered therapeutic agent.
o ACT® is supported by a strong and broad preclinical package demonstrating
therapeutic enhancement in multiple oncology models (pancreatic, breast, colon,
prostate) as well as blood-brain barrier penetration.
o Initial focus of the Company is oncology, however, the ACT® platform has
potential across multiple therapeutic areas (infectious diseases, CNS,
immunotherapy) and classes of therapeutic agents.